Tenofovir: A Comprehensive Monograph on a Cornerstone Antiviral Agent

Executive Summary

Tenofovir is an acyclic nucleotide phosphonate analog of adenosine monophosphate that has become a cornerstone in the global strategy against viral diseases, particularly Human Immunodeficiency Virus (HIV) and chronic Hepatitis B (CHB). As a potent inhibitor of viral reverse transcriptase and DNA polymerase, its mechanism of action relies on intracellular activation to its diphosphate form, which competitively inhibits viral replication and acts as an obligatory DNA chain terminator. Due to the poor oral bioavailability of the active moiety, its clinical utility has been realized through two successive prodrug formulations: tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).

The development from TDF to TAF represents a significant triumph in medicinal chemistry, aimed at optimizing the drug's therapeutic index. TDF, while highly effective, is associated with high systemic plasma concentrations of tenofovir, leading to dose-limiting renal and bone toxicities. TAF, a more advanced phosphonamidate prodrug, was engineered for greater plasma stability and preferential intracellular activation. This allows for much lower oral doses, resulting in over 90% lower systemic tenofovir exposure while achieving higher concentrations of the active metabolite in target lymphoid cells. This targeted delivery mechanism translates into a demonstrably improved renal and bone safety profile. However, this benefit is counterbalanced by a less favorable metabolic profile, including potential weight gain and lipid elevations, creating a nuanced clinical choice between the two formulations.

Tenofovir, in both its TDF and TAF forms, is a recommended component of first-line antiretroviral therapy (ART) in major international guidelines for the treatment of HIV and CHB. Furthermore, the TDF/emtricitabine combination is a critical tool for HIV pre-exposure prophylaxis (PrEP). The patent expiration of TDF has dramatically altered the commercial landscape, enabling widespread access to affordable generic versions, which is crucial for public health initiatives in resource-limited settings. In contrast, TAF remains under patent protection, creating a global dichotomy between cost and safety profile that influences clinical practice.

Ongoing research is focused on overcoming the challenge of daily oral dosing. The development of long-acting formulations, such as subdermal implants and parenteral injectables, represents the next frontier for tenofovir, aiming to improve patient adherence and quality of life. The story of tenofovir—from its initial chemical challenge to its evolution through sophisticated prodrugs and its future in long-acting delivery systems—serves as a compelling case study in the maturation of chronic viral disease management in the 21st century.

I. Chemical Identity and Physicochemical Properties

The clinical application and pharmacological behavior of tenofovir are fundamentally dictated by its chemical structure and properties. The inherent challenge of delivering the charged active molecule into the body necessitated the development of sophisticated prodrugs, each with distinct chemical characteristics.

1.1. Nomenclature and Identifiers

Tenofovir is the common name for the active antiviral compound. However, in clinical practice, it is administered via one of its prodrugs.

• Tenofovir (Active Moiety)
• **Systematic (IUPAC) Name:**oxymethylphosphonic acid.[1]
• CAS Registry Number: 147127-20-6.[2]
• DrugBank ID: DB14126.[2]
• Synonyms: (R)-9-(2-Phosphonomethoxypropyl)adenine; PMPA.[3]
• Chemical Identifiers:
• InChI: InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1.[3]
• InChIKey: SGOIRFVFHAKUTI-ZCFIWIBFSA-N.[3]
• Canonical SMILES: C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O.[1]
• Tenofovir Disoproxil Fumarate (TDF)
• Description: TDF is the fumarate salt of tenofovir disoproxil, the first-generation prodrug.[5] The disoproxil ester masks the phosphonate group, and the fumarate salt improves the stability and handling of the compound.
• CAS Registry Number: 202138-50-9 (fumarate salt).[5]
• **IUPAC Name (ester):**oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate.[5]
• Tenofovir Alafenamide (TAF)
• Description: TAF is a second-generation phosphonamidate prodrug of tenofovir, typically formulated as a hemifumarate salt.[6] Its distinct chemical linkage is key to its altered pharmacokinetic profile.
• IUPAC Name: 9-amino]phenoxyphosphinyl]methoxy]propyl]adenine.[6]

1.2. Molecular Structure and Formulae

The core structure is an acyclic phosphonate analog of adenosine monophosphate, where the furanose ring is replaced by an acyclic side chain.[2] The stereochemistry is critical, with the (R)-isomer being the active configuration.[3]

• Tenofovir: The molecular formula is C9​H14​N5​O4​P, with a molecular weight of 287.21 g/mol.[1]
• Tenofovir Disoproxil: The molecular formula is C19​H30​N5​O10​P, with a molecular weight of 519.4 g/mol.[9] This structure results from the esterification of the phosphonic acid with two isopropoxycarbonyloxymethyl (disoproxil) groups.
• Tenofovir Alafenamide: The molecular formula is C21​H29​N6​O5​P. The structure features a more complex phosphonamidate linkage involving L-alanine isopropyl ester and a phenyl group, designed for enhanced stability in plasma.[8]

1.3. Physical and Chemical Properties

The physicochemical properties of tenofovir and its prodrugs explain their biological behavior, particularly the need for the prodrug approach.

Table 1: Physicochemical Properties of Tenofovir and its Prodrugs

Property	Tenofovir (Active Moiety)	Tenofovir Disoproxil Fumarate (TDF)	Tenofovir Alafenamide (TAF)
Molecular Formula	C9​H14​N5​O4​P	C23​H34​N5​O14​P (fumarate salt)	C21​H29​N6​O5​P (base)
Molecular Weight	287.21 g/mol	635.52 g/mol (fumarate salt)	476.47 g/mol (base)
Physical State	White to off-white crystalline powder	White, fine, powder-like crystals	Data not available
Melting Point	276–280 °C	113–115 °C	Data not available
Water Solubility	13.4 mg/mL	13.4 mg/mL (at 25 °C)	Data not available
pKa	3.8, 6.7	3.75	Data not available
LogP	-1.6	1.25	Data not available

Data sourced from.[1]

1.4. The Prodrug Imperative

The data presented in Table 1 provides a clear chemical rationale for the development of tenofovir prodrugs. The active moiety, tenofovir, possesses a phosphonate group that is ionized with two negative charges at physiological pH. This results in a highly polar molecule, as quantified by its negative LogP value of -1.6, which signifies its preference for aqueous environments over lipid membranes.[1] This polarity severely restricts its ability to passively diffuse across the lipid bilayer of the intestinal epithelium, leading to very low oral bioavailability when administered directly.[2]

To overcome this fundamental absorption barrier, medicinal chemists designed prodrugs. The first-generation prodrug, TDF, masks the charged phosphonate with two lipophilic disoproxil ester groups. This chemical modification dramatically increases the molecule's lipophilicity, as evidenced by the positive LogP value of 1.25 for the prodrug.[9] This change allows the TDF molecule to be absorbed orally. Once in the systemic circulation, plasma esterases cleave these ester groups, releasing the active tenofovir.[12] The development of TAF represents a further refinement of this strategy, employing a different chemical linkage (phosphonamidate) designed not only to facilitate absorption but also to control the location of activation, thereby optimizing the drug's therapeutic index.[8]

II. Pharmacology and Mechanism of Action

Tenofovir's potent antiviral activity stems from its precise interference with essential viral replication enzymes. Its pharmacology is characterized by the requirement for intracellular activation and a pharmacokinetic profile that has been deliberately engineered through its prodrug forms to maximize efficacy while minimizing toxicity.

2.1. Pharmacodynamics: The Molecular Basis of Antiviral Activity

2.1.1. Intracellular Activation

Tenofovir is administered as an inactive prodrug, either TDF or TAF. Following absorption, these prodrugs are hydrolyzed to release the parent compound, tenofovir.[7] The critical step for antiviral activity occurs within the host's target cells, such as lymphocytes. Cellular kinases recognize tenofovir and perform a two-step phosphorylation, converting it first to tenofovir monophosphate and subsequently to the pharmacologically active metabolite, tenofovir diphosphate (TFV-DP).[2] This metabolic activation is a prerequisite for its function.

2.1.2. Inhibition of Viral Enzymes

The active metabolite, TFV-DP, is the agent of viral suppression. It is a structural analog of the natural deoxyribonucleotide, deoxyadenosine 5'-triphosphate (dATP).[13]

• Human Immunodeficiency Virus (HIV): TFV-DP exerts its primary effect by potently inhibiting the HIV-1 reverse transcriptase (RT) enzyme. It acts via competitive inhibition, binding to the enzyme's active site with high affinity and competing directly with the endogenous dATP substrate.[2]
• Hepatitis B Virus (HBV): A similar mechanism is at play in HBV-infected cells. TFV-DP inhibits the HBV DNA polymerase, another viral enzyme that relies on dATP for viral DNA synthesis.[13]

2.1.3. Mechanism of Viral DNA Chain Termination

Beyond competitive inhibition, tenofovir's most definitive action is as an obligatory chain terminator. After TFV-DP is mistakenly incorporated by the viral polymerase into the nascent viral DNA strand, it irrevocably halts further elongation of the chain.[2] This occurs because tenofovir is an acyclic nucleotide; its structure lacks the crucial 3'-hydroxyl (

3′-OH) group that is required to form a phosphodiester bond with the next incoming nucleotide.[13] By preventing the completion of a functional viral genome, tenofovir effectively terminates the replication cycle.

2.1.4. Selectivity and Safety

The clinical success of tenofovir is partly due to its selective toxicity. TFV-DP has a significantly lower affinity for human cellular DNA polymerases (α and β) and, critically, for mitochondrial DNA polymerase γ, compared to its high affinity for viral polymerases.[2] This selectivity ensures that host cell DNA replication is minimally affected at therapeutic concentrations, which accounts for its improved safety profile relative to older nucleoside reverse transcriptase inhibitors (NRTIs) like stavudine, which had more pronounced mitochondrial toxicity.[2]

2.2. Pharmacokinetics (PK): A Tale of Two Prodrugs

The distinct pharmacokinetic profiles of TDF and TAF are central to their differing clinical characteristics and represent a clear evolution in drug design.

2.2.1. Absorption

• TDF: Following oral administration, TDF has a bioavailability of approximately 25% in the fasting state. This can be enhanced by co-administration with a high-fat meal, which increases the area under the curve (AUC) by about 40%.[12] Upon absorption, TDF is subject to rapid and extensive hydrolysis by esterases in the gut, blood, and tissues, quickly converting it into tenofovir systemically.[12]
• TAF: TAF is designed for greater stability in plasma. It is a substrate of the drug transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). Taking TAF with a high-fat meal increases its exposure by 65%.[7] Its enhanced stability allows a greater proportion of the intact prodrug to be absorbed and distributed to target cells before being converted to tenofovir.[8]

2.2.2. Distribution

The distribution patterns of the two prodrugs are the key to their different safety profiles.

• TDF: Administration of a 300 mg dose of TDF results in high systemic plasma concentrations of tenofovir, with a Cmax of approximately 300 ng/mL and an AUC of around 3000 ng·h/mL.[16] Tenofovir itself has low plasma protein binding (<0.7%) and distributes with a volume of approximately 0.8 L/kg.[2] This high level of circulating tenofovir exposes non-target tissues, particularly the kidneys and bones, to the drug.
• TAF: In stark contrast, a 25 mg dose of TAF results in plasma tenofovir concentrations that are over 90% lower than those seen with a 300 mg TDF dose.[8] Despite this, the efficient intracellular delivery mechanism of TAF leads to significantly higher concentrations of the active metabolite, TFV-DP, within target cells like peripheral blood mononuclear cells (PBMCs).[8] TAF itself is highly protein-bound (~80%).[7] This profile—low systemic exposure, high intracellular concentration—is the pharmacological basis for TAF's improved renal and bone safety.

2.2.3. Metabolism

• TDF: The prodrug is rapidly cleaved by non-specific esterases throughout the body.[12] The resulting tenofovir is not a substrate for, nor does it inhibit or induce, cytochrome P450 (CYP450) enzymes, minimizing the potential for many common drug-drug interactions.[12]
• TAF: The TAF prodrug is metabolized primarily intracellularly by cathepsin A, an enzyme highly expressed in lymphocytes and other target cells, and by carboxylesterase-1 in hepatocytes.[7] This targeted activation is a key design feature.

2.2.4. Excretion

Tenofovir, whether derived from TDF or TAF, is eliminated from the body primarily by the kidneys. The process involves a combination of glomerular filtration and active tubular secretion via the human organic anion transporters hOAT1 and hOAT3, and the multidrug resistance-associated protein 4 (MRP4).[12] This active secretion mechanism is responsible for concentrating tenofovir within renal proximal tubule cells. The high systemic tenofovir levels produced by TDF saturate this pathway, directly contributing to the risk of nephrotoxicity. Tenofovir has a plasma half-life of approximately 12 to 18 hours, which supports convenient once-daily dosing.[12]

2.3. Resistance Profile

Tenofovir possesses a relatively high genetic barrier to the development of resistance, a key attribute for a long-term antiviral agent.[13] The primary mutation associated with reduced susceptibility to tenofovir in HIV is the K65R substitution in the reverse transcriptase enzyme. This mutation confers only a modest (2- to 4-fold) decrease in susceptibility.[15] Importantly, the K65R mutation can impair the virus's replicative capacity, or "fitness," which may slow the emergence of resistant strains in clinical practice.[13] This robust resistance profile has contributed to its durability as a preferred component of ART.

III. Clinical Efficacy and Therapeutic Applications

Tenofovir has established itself as a versatile and indispensable agent in the clinical management and prevention of major viral infections. Its potent activity, favorable resistance profile, and convenient once-daily dosing have led to its inclusion in numerous therapeutic regimens worldwide.

3.1. Approved Indications

Tenofovir, through its prodrug formulations, has secured regulatory approval for three primary indications.

3.1.1. Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection

Tenofovir is a cornerstone of modern combination antiretroviral therapy (cART). It is indicated, always in combination with other antiretroviral agents, for the treatment of HIV-1 infection in both treatment-naive and treatment-experienced patients.[2] Its use is approved in adults and in pediatric patients, with specific age and weight criteria depending on the formulation.[18]

3.1.2. Treatment of Chronic Hepatitis B (CHB) Infection

Both TDF and TAF are indicated for the treatment of chronic HBV infection.[18] Due to its high efficacy in suppressing HBV DNA and its high barrier to resistance, tenofovir is recommended as a first-line agent in major treatment guidelines.[20] The TAF formulation (Vemlidy) is specifically approved for adults and pediatric patients with compensated liver disease.[26]

3.1.3. Pre-Exposure Prophylaxis (PrEP) for HIV-1 Prevention

The use of tenofovir for PrEP represents a paradigm shift in HIV prevention, moving from behavioral interventions to biomedical prevention for at-risk individuals.

• TDF/Emtricitabine (Truvada): This fixed-dose combination is FDA-approved to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg.[28] Its efficacy is highly dependent on adherence.
• TAF/Emtricitabine (Descovy): This combination is also approved for PrEP. However, its indication specifically excludes individuals at risk of acquiring HIV through receptive vaginal sex, as its efficacy has not been established in that population.[30]

3.2. Dosing and Administration

Dosing of tenofovir is highly specific to the indication, patient population (age and weight), and renal function.

Table 3: Approved Indications and Dosing Regimens for Tenofovir Formulations

Indication	Patient Population	Formulation	Standard Dose	Renal Dosing Adjustment (CrCl)	Key Administration Notes
HIV-1 Treatment	Adults & Peds ≥35 kg	TDF	300 mg once daily	30–49 mL/min: 300 mg q48h 10–29 mL/min: 300 mg q72–96h Hemodialysis: 300 mg q7d	Take with or without food.
	Peds (by weight)	TDF Tablets or Powder	8 mg/kg once daily (max 300 mg)	Not recommended in peds with renal impairment.	Powder must be mixed with soft food.
	Adults & Peds ≥35 kg	TAF (in FDC)	25 mg once daily	≥30 mL/min: No adjustment 15–29 mL/min: No adjustment <15 mL/min (HD): Give after dialysis	Take with food.
Chronic Hepatitis B	Adults & Peds ≥12 yrs	TDF	300 mg once daily	Same as HIV treatment.	Take with or without food.
	Adults & Peds ≥12 yrs	TAF (Vemlidy)	25 mg once daily	≥15 mL/min: No adjustment <15 mL/min (not on HD): Not recommended	Take with food.
HIV-1 PrEP	Adults & Adol. ≥35 kg	TDF/FTC	300 mg/200 mg once daily	<60 mL/min: Not recommended.	Take with or without food.
	Adults & Adol. ≥35 kg	TAF/FTC	25 mg/200 mg once daily	<30 mL/min: Not recommended (unless on HD).	Take with or without food.

Data sourced from.[18] FDC = Fixed-Dose Combination. HD = Hemodialysis.

The stark contrast in renal dosing adjustments between TDF and TAF in the table above is a direct clinical manifestation of their differing pharmacokinetic profiles. The need for complex interval adjustments for TDF in patients with even moderate renal impairment presents a significant clinical challenge, which is largely obviated by the use of TAF.

3.3. Off-Label and Investigational Uses

Tenofovir's potent and well-characterized antiviral activity has led to its use and investigation beyond its formally approved indications.

• Post-Exposure Prophylaxis (PEP): The combination of TDF/emtricitabine is a recommended backbone for preferred 28-day PEP regimens following potential occupational (oPEP) or non-occupational (nPEP) exposure to HIV.[33]
• On-Demand PrEP: Also known as "2-1-1" or "event-driven" PrEP, this off-label dosing strategy for TDF/emtricitabine has been shown to be effective for men who have sex with men (MSM). It involves taking two tablets 2 to 24 hours before anticipated sexual activity, followed by one tablet 24 hours after the initial dose and another tablet 48 hours after the initial dose.[30]
• Topical Microbicides: Tenofovir has been studied in topical formulations, such as vaginal and rectal gels or douches, as a potential method to prevent sexual HIV transmission directly at the site of exposure. Several clinical trials have explored this application, though the focus in prevention has largely shifted to more effective systemic approaches like oral PrEP and long-acting injectables.[28]

The clinical journey of tenofovir illustrates a powerful trend in modern medicine. Initially approved as a salvage therapy for treatment-experienced HIV patients, its robust efficacy and favorable safety profile compared to its predecessors propelled it to become a first-line agent for treatment-naive individuals.[19] This confidence grew further, leading to its approval for a second chronic viral illness, CHB.[18] The ultimate testament to its well-understood risk-benefit profile was its groundbreaking approval for PrEP, where a potent drug is prescribed to healthy individuals to prevent infection.[29] This trajectory, from reactive treatment to proactive prevention, showcases how a successful therapeutic can evolve into a transformative public health tool, fundamentally altering the epidemiology of a disease. The development of TAF is a logical continuation of this arc, aiming to make lifelong therapy or prophylaxis even safer and more sustainable.

IV. Comparative Analysis: Tenofovir Disoproxil Fumarate (TDF) vs. Tenofovir Alafenamide (TAF)

The transition from TDF to TAF is a pivotal chapter in the history of antiretroviral therapy and a case study in targeted drug design. While both are prodrugs of tenofovir, their distinct chemical structures lead to profoundly different pharmacokinetic profiles, which in turn creates a nuanced trade-off between efficacy, safety, and cost.

4.1. Pharmacokinetic and Pharmacodynamic Differentiation

The central thesis behind TAF's development was to create a more efficient tenofovir delivery system. TDF is rapidly hydrolyzed in the plasma, flooding the systemic circulation with tenofovir before it reaches target cells.[12] In contrast, TAF, a phosphonamidate prodrug, is designed to be significantly more stable in plasma. This stability allows the intact prodrug to circulate and be taken up by target cells (like lymphocytes and hepatocytes), where it is then efficiently hydrolyzed by the intracellular enzyme cathepsin A.[8]

This difference in activation strategy has a dramatic quantitative impact. A standard 25 mg oral dose of TAF yields plasma tenofovir concentrations that are more than 90% lower than those from a 300 mg dose of TDF. Despite this massive reduction in systemic exposure, TAF achieves 4- to 7-fold higher intracellular concentrations of the active metabolite, tenofovir diphosphate (TFV-DP), within the target peripheral blood mononuclear cells.[8] This "high intracellular, low systemic" profile is the key to TAF's altered clinical effects.

Table 2: Comparative Pharmacokinetic Parameters of TDF and TAF

Parameter	TDF (300 mg dose)	TAF (25 mg dose)	Key Finding
Plasma Tenofovir Cmax	~300 ng/mL	~15 ng/mL	>90% reduction with TAF
Plasma Tenofovir AUC	~3000 ng·h/mL	~383 ng·h/mL	>85% reduction with TAF
Intracellular TFV-DP AUC (in PBMCs)	Lower	4-7 fold Higher	TAF achieves superior target cell loading
Plasma Half-life (Prodrug)	Very short (minutes)	~0.51 hours	TAF is more stable in plasma
Plasma Half-life (Tenofovir)	~17 hours	~32 hours	Long half-life supports once-daily dosing for both

Data sourced from.[7] AUC = Area Under the Curve. Cmax = Maximum Concentration. PBMCs = Peripheral Blood Mononuclear Cells.

4.2. Comparative Efficacy

In numerous large-scale, randomized clinical trials for the treatment of HIV, TAF-based regimens have consistently demonstrated non-inferior virologic suppression rates when compared directly to their TDF-based counterparts.[11] However, this conclusion requires significant nuance. A comprehensive meta-analysis involving 14 trials and nearly 15,000 patients revealed a critical distinction: while TAF showed a statistically significant, albeit marginal, efficacy advantage over TDF in regimens that were

boosted with a pharmacokinetic enhancer like ritonavir or cobicistat, there was no significant difference in efficacy between the two prodrugs when used in unboosted regimens.[35] This is a crucial finding, as modern ART has largely moved towards unboosted integrase inhibitor-based regimens. This suggests that for a large and growing proportion of patients on current standard-of-care therapy, the virologic efficacy of TAF and TDF is equivalent.

4.3. The Evolution of Safety: A Profile Trade-Off

The primary clinical driver for the development and adoption of TAF was its superior safety profile with respect to renal function and bone health.

• Renal and Bone Safety: The lower systemic plasma tenofovir concentrations achieved with TAF directly translate into reduced exposure for the kidneys and bones. Numerous studies have confirmed that, compared to TDF, TAF is associated with significantly smaller decreases in estimated glomerular filtration rate (eGFR), less proteinuria, and markedly smaller reductions in bone mineral density (BMD) at the hip and spine.[11] This makes TAF a clearly preferred agent for patients with or at high risk for chronic kidney disease or osteoporosis.
• Metabolic Safety: The improved renal and bone safety of TAF is not absolute and comes with a metabolic trade-off. Compared to TDF, TAF has been consistently associated with less favorable changes in lipid profiles, including increases in total cholesterol, LDL-cholesterol, and triglycerides. Furthermore, patients switching from TDF to TAF, or starting TAF-based regimens, often experience more significant weight gain.[30] These effects introduce a different set of long-term health concerns, particularly related to cardiovascular risk, that must be weighed against the renal and bone benefits.

Table 6: Summary of TDF vs. TAF Clinical Profile

Clinical Endpoint	TDF Profile	TAF Profile	Nuance/Consideration
Virologic Efficacy (HIV)	High; non-inferior to TAF in unboosted regimens	High; superior to TDF only in boosted regimens	Most modern regimens are unboosted, making efficacy largely equivalent.
Renal Safety (e.g., eGFR)	Associated with greater declines in eGFR and proteinuria	Significantly less impact on renal function markers	TAF is preferred in patients with renal risk.
Bone Safety (BMD)	Associated with greater decreases in bone mineral density	Significantly less impact on BMD	TAF is preferred in patients with osteoporosis risk.
Lipid Profile (LDL, TG)	Generally neutral or slightly favorable impact	Associated with increases in LDL and triglycerides	TDF may be preferred in patients with high cardiovascular risk.
Weight Gain	Minimal impact	Associated with greater weight gain	A significant concern for metabolic health.

Data sourced from.[11]

4.4. Clinical Implications and Guideline Recommendations

The choice between TDF and TAF is a prime example of personalized medicine, requiring a careful assessment of an individual patient's comorbidities and risk factors. TAF is the logical choice for patients with pre-existing renal disease or significant risk factors for bone density loss. Conversely, for a young, healthy patient with no renal or bone issues but with a family history of cardiovascular disease or concerns about metabolic syndrome, the cheaper, generic TDF with its more favorable metabolic profile may be an equally appropriate, or even preferred, choice.

This clinical decision is further complicated by socioeconomic and health-system factors. The patent protection for TAF extends into the 2030s, making it a high-cost, branded drug, while TDF is widely available as an inexpensive generic.[6] This price disparity has created a de facto two-tiered system of access globally. In resource-rich countries, the switch to TAF has been widespread, while in many resource-limited settings, the affordability of generic TDF is essential for maintaining broad access to life-saving ART. This situation is underscored by controversy and litigation alleging that the originator, Gilead Sciences, strategically delayed the market entry of the safer TAF to maximize revenue from its TDF-based products before their patents expired.[36]

V. Safety, Tolerability, and Risk Management

While tenofovir is generally well-tolerated, particularly its newer TAF formulation, its use is associated with a distinct profile of potential adverse events that require careful monitoring and management. Its safety profile is dominated by effects related to its renal route of elimination and its class effects as a nucleoside reverse transcriptase inhibitor.

5.1. Comprehensive Adverse Event Profile

5.1.1. Common Adverse Reactions

The most frequently reported adverse reactions are generally mild to moderate and can vary slightly between the prodrug formulations.

• TDF: In HIV-infected adults, common adverse reactions with an incidence of 10% or greater include rash, diarrhea, nausea, headache, pain, depression, and asthenia (generalized weakness).[39] In patients with chronic hepatitis B, nausea is the most common side effect.[39]
• TAF: Common side effects reported with TAF-containing regimens include headache, abdominal pain, cough, and nausea.[40]

5.1.2. Serious Adverse Reactions and Boxed Warnings

Both TDF and TAF carry warnings for several potentially severe adverse reactions.

• Post-Treatment Severe Acute Exacerbation of Hepatitis B: This is a critical boxed warning. Patients with chronic hepatitis B who discontinue tenofovir therapy are at risk of a severe flare-up of their hepatitis, which can lead to hepatic decompensation and liver failure. Therefore, patients must be closely monitored with clinical and laboratory follow-up (e.g., liver function tests) for at least several months after stopping the drug. Resumption of anti-hepatitis B therapy may be necessary.[26]
• New Onset or Worsening Renal Impairment: This risk is primarily associated with TDF due to its high plasma concentrations. Tenofovir is eliminated by the kidneys, and its use can lead to renal impairment, including cases of acute renal failure and Fanconi syndrome, a specific type of renal tubular injury characterized by severe hypophosphatemia (phosphate wasting).[2] Risk factors for nephrotoxicity include pre-existing kidney disease, low body weight, advanced age, and the use of other nephrotoxic drugs.[42]
• Decreases in Bone Mineral Density (BMD) and Osteomalacia: This adverse effect is also predominantly linked to TDF. The drug can cause decreases in BMD at the hip and spine and, in cases of severe renal tubulopathy, can lead to osteomalacia (softening of the bones).[2] This is thought to be a consequence of the phosphate wasting associated with Fanconi syndrome.
• Lactic Acidosis and Severe Hepatomegaly with Steatosis: This is a rare but life-threatening class-effect toxicity associated with NRTIs. It involves the buildup of lactic acid in the blood and fatty liver, which can be fatal. The risk is higher in female patients, those with obesity, and with prolonged NRTI use.[27]
• Immune Reconstitution Inflammatory Syndrome (IRIS): In HIV-infected patients initiating cART, the recovering immune system may mount an exaggerated inflammatory response to pre-existing, subclinical opportunistic infections (e.g., Mycobacterium avium complex, cytomegalovirus). This can cause a temporary worsening of symptoms and requires management.[26]

5.2. Clinically Significant Drug-Drug Interactions

Table 4: Clinically Significant Drug-Drug Interactions and Management

Interacting Drug/Class	Effect on Tenofovir or Concomitant Drug	Proposed Mechanism	Clinical Management Recommendation
Nephrotoxic Agents (e.g., NSAIDs, aminoglycosides, acyclovir, cidofovir)	Increases TDF/tenofovir concentrations and risk of renal toxicity.	Additive nephrotoxicity and/or competition for active tubular secretion via OAT1/3.	Avoid concurrent or recent use, especially with TDF. If unavoidable, monitor renal function closely. Consider alternatives to NSAIDs.
P-gp Inducers (e.g., Rifampin, St. John's Wort, Carbamazepine)	Decreases TAF plasma concentrations, potentially reducing efficacy.	Induction of P-glycoprotein (P-gp), which transports TAF.	Co-administration is not recommended.
Boosted Protease Inhibitors (e.g., Lopinavir/ritonavir, Atazanavir/ritonavir)	Increases tenofovir concentrations from TDF.	Inhibition of renal transporters (e.g., MRP4) by the booster (ritonavir/cobicistat).	Monitor for tenofovir-associated adverse reactions (e.g., renal toxicity).
Atazanavir	TDF decreases atazanavir concentrations.	Unknown.	Atazanavir must be co-administered with a booster (ritonavir or cobicistat) when used with TDF.
Didanosine	TDF increases didanosine concentrations.	Unknown.	Use with caution. Monitor for didanosine toxicity (pancreatitis, neuropathy) and consider didanosine dose reduction.

Data sourced from.[2]

5.3. Use in Special Populations

• Pregnancy: TDF has a long track record of use and is considered a preferred NRTI for treating HIV in pregnancy.[33] TAF is now also part of a preferred regimen (bictegravir/TAF/emtricitabine) for use during pregnancy and for those trying to conceive.[44]
• Renal Impairment: As detailed previously, TDF requires significant dose interval adjustments based on creatinine clearance, while TAF offers a much simpler dosing regimen for patients with renal impairment.[7]
• Hepatic Impairment: No dose adjustment is required for either TDF or TAF in patients with mild (Child-Pugh A) hepatic impairment. TAF is not recommended for patients with decompensated (Child-Pugh B or C) liver disease.[7]
• HIV/HBV Co-infection: It is critical that patients co-infected with HIV and HBV receive a cART regimen that includes agents active against both viruses (e.g., tenofovir plus emtricitabine or lamivudine). Using tenofovir alone in an HIV-positive patient can lead to the development of HIV resistance. Therefore, all patients should be tested for HBV before initiating tenofovir for HIV, and all patients should be tested for HIV before initiating TAF for HBV.[26]

5.4. Monitoring Parameters and Risk Mitigation Strategies

To ensure the safe use of tenofovir, a schedule of regular monitoring is essential.

• Baseline Assessment: Before starting therapy, all patients should have their serum creatinine, estimated creatinine clearance (eCrCl), urine glucose, and urine protein assessed. HIV antibody testing should be offered to all HBV-infected patients, and HBV testing should be performed for all HIV-infected patients.[21]
• Ongoing Monitoring: Renal function parameters should be monitored on a clinically appropriate schedule during treatment. In patients with chronic kidney disease, serum phosphorus should also be monitored.[27]
• PrEP Monitoring: For individuals on PrEP, HIV-1 screening tests must be performed before initiation and repeated at least every 3 months to ensure they remain HIV-negative and to prevent the development of drug resistance.[31]

VI. Regulatory and Commercial Landscape

The journey of tenofovir from a novel chemical entity to a global blockbuster and finally to a widely available generic is a story of scientific innovation, strategic commercialization, and public health impact. Its regulatory history and patent lifecycle have profoundly shaped access to HIV and HBV treatment worldwide.

6.1. Global Regulatory History and Key FDA Approval Milestones

The U.S. Food and Drug Administration (FDA) approvals for tenofovir and its formulations mark key moments in its clinical integration.

Table 5: Summary of Key FDA Approval Milestones and Patent Expiration Dates

Year	Drug/Formulation	Event	Significance/Note
2001	Viread® (TDF)	Initial Approval	First nucleotide reverse transcriptase inhibitor (NtRTI) approved for treatment-experienced HIV-1 patients.
2004	Truvada® (TDF/FTC)	FDC Approval	Simplified HIV treatment regimens by combining two NRTIs into a single tablet.
2008	Viread® (TDF)	New Indication	Approved for the treatment of chronic hepatitis B, expanding its use beyond HIV.
2012	Viread® (TDF)	New Formulations	Pediatric oral powder and lower-strength tablets approved, expanding access to children.
2012	Truvada® (TDF/FTC)	New Indication	Landmark approval for HIV Pre-Exposure Prophylaxis (PrEP), a new paradigm in prevention.
2015	Genvoya® (TAF FDC)	TAF First Approval	First approval of the second-generation prodrug TAF, as part of a single-tablet regimen for HIV.
2016	Vemlidy® (TAF)	Monotherapy Approval	TAF approved as a standalone agent for chronic hepatitis B.
2016	Descovy® (TAF/FTC)	FDC Approval	TAF/emtricitabine combination approved for HIV treatment. Later approved for PrEP.
~2017-18	TDF	Patent Expiration	Key patents for TDF expire in the US and Europe, opening the door for generic competition.
2032	TAF	Patent Expiration	Key patents protecting TAF and its salts are expected to expire, maintaining market exclusivity.

Data sourced from.[6] FDC = Fixed-Dose Combination.

6.2. Patent Lifecycle and the Advent of Generic Competition

The patent strategy surrounding tenofovir has been a defining feature of its commercial history. The original compound patent for tenofovir was filed by the Czech Academy of Science in 1985 and has long since expired.[46] The clinical utility and commercial success, however, were tied to the patents on the prodrugs developed by Gilead Sciences.

• TDF Patent Expiry: The key patents protecting the TDF prodrug expired in most major markets, including the United States and Europe, around 2017-2018.[38] This event was a watershed moment, paving the way for numerous generic manufacturers to enter the market. The resulting competition led to a dramatic and rapid decrease in the price of TDF-based regimens, significantly expanding access to affordable, first-line ART and PrEP, particularly in low- and middle-income countries that rely on generic procurement.[38]
• TAF Patent Exclusivity: In contrast, TAF is protected by a robust portfolio of later-filed patents covering its specific chemical structure, its hemifumarate salt form, and its use in various combinations. These patents are not expected to expire until the early 2030s (e.g., August 15, 2032, for key patents).[6] This long period of market exclusivity ensures that TAF-based regimens remain high-cost, branded products, creating the clinical and economic dichotomy with generic TDF.
• The TDF-to-TAF Transition Controversy: The timing of these events has been the subject of significant scrutiny and litigation. Lawsuits have alleged that Gilead Sciences intentionally delayed the clinical development and launch of TAF, which it knew to have a better safety profile, in order to maximize the patent-protected revenue from its TDF-based products before they faced generic competition.[36] The timeline presented in Table 5, showing a nearly 14-year gap between the initial approval of TDF and the first approval of a TAF-containing regimen, provides context for these claims.

6.3. Key Originator and Generic Manufacturers

• Originator: Gilead Sciences, Inc. is the original developer of both tenofovir prodrugs and has marketed them under various brand names, including Viread® (TDF), Vemlidy® (TAF), and as components in market-leading fixed-dose combinations like Truvada®, Atripla®, Stribild®, Genvoya®, Odefsey®, and Descovy®.[5]
• Generic Manufacturers: The generic TDF market is highly competitive. A large number of pharmaceutical companies now produce generic TDF and its combinations. Prominent manufacturers with FDA-approved generic versions include Teva Pharmaceuticals, Aurobindo Pharma, Cipla, Mylan (now Viatris), Hetero Labs, Macleods Pharmaceuticals, Amneal, Laurus Labs, and Zydus Pharmaceuticals.[48]

VII. Tenofovir in Modern Antiviral Therapy: Guideline Placement and Future Perspectives

After two decades of clinical use, tenofovir remains a central pillar of antiviral therapy. Its placement in treatment guidelines is secure, but its role continues to evolve in response to new research, the availability of other drug classes, and the ongoing quest for more convenient and durable treatment strategies.

7.1. Role in International HIV and HBV Treatment Guidelines

Tenofovir's efficacy, durability, and well-characterized safety profile have earned it a preferred status in major international treatment guidelines.

• HIV Guidelines (HHS, IAS-USA, WHO): Regimens built on a two-drug NRTI backbone are the standard of care for initial HIV treatment. Tenofovir (as either TDF or TAF) combined with emtricitabine (or lamivudine) forms the most commonly recommended backbone.[20] The choice between the TDF and TAF formulation is left to clinical judgment, based on a patient's individual risk profile for renal, bone, and cardiovascular disease.[55]
• HBV Guidelines (AASLD): The American Association for the Study of Liver Diseases recommends both TDF and TAF as preferred first-line monotherapies for adults with chronic hepatitis B.[56] Their high potency and high genetic barrier to resistance make them superior to older agents like lamivudine or adefovir. The 2018 AASLD guidance update specifically incorporated recommendations for the use of TAF following its approval.[57]
• PrEP Guidelines (CDC, WHO): The combination of TDF/emtricitabine is a cornerstone of global HIV prevention strategies and is recommended as a primary oral PrEP option.[58] TAF/emtricitabine is also a recommended option, particularly for men who have sex with men, but its use is limited by the lack of efficacy data for receptive vaginal sex.[30]

7.2. Comparative Efficacy and Safety Against Other Antiretrovirals

• Versus Older NRTIs: Tenofovir has demonstrated a superior profile compared to older NRTIs. A Cochrane review comparing TDF to zidovudine (AZT) found that TDF-containing regimens led to better immunologic responses and higher rates of adherence, with equivalent virologic suppression.[34] Compared to abacavir, tenofovir does not carry the risk of a potentially fatal hypersensitivity reaction and does not require HLA-B*5701 genetic screening.
• As Part of Single-Tablet Regimens (STRs): The tenofovir/emtricitabine backbone is a component of many of the most widely prescribed STRs. For example, the TAF-based STR Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) has shown excellent long-term durability and a favorable safety profile in large clinical trials, solidifying the role of the TAF/FTC backbone in modern therapy.[60]

7.3. Horizon Scan: Ongoing Research and Development

The developmental arc of tenofovir is a clear illustration of the evolution of chronic disease management. The initial focus was on achieving efficacy, which was accomplished with TDF. The next phase prioritized optimizing long-term safety and tolerability, leading to the development of TAF. The current and future focus is on maximizing adherence and improving quality of life, which is driving research into long-acting formulations.

7.3.1. Long-Acting (LA) Formulations

The most significant area of ongoing research is the development of LA versions of tenofovir to eliminate the need for daily oral dosing, a major barrier to adherence.

• Subdermal Implants: Active research is exploring the potential of subdermal implants capable of providing sustained, controlled release of TAF for HIV prophylaxis. Preclinical studies in mouse models are underway to characterize the pharmacokinetics and determine the effective dose needed to prevent HIV acquisition, with the goal of creating an implant that could last for six months or more.[62]
• Parenteral Injectables: While LA injectables of other antiretroviral classes are now approved (e.g., the integrase inhibitor cabotegravir and the capsid inhibitor lenacapavir), developing an injectable NRTI like tenofovir is more challenging due to the inherent hydrophilicity of the molecules.[59] Current research focuses on creating novel, highly lipophilic prodrugs of tenofovir and emtricitabine that can be formulated as stable nanocrystal suspensions suitable for intramuscular injection, with the aim of achieving dosing intervals of one month or longer.[65]

7.3.2. Novel Combination Therapies and Long-Term Outcome Studies

Research continues to reinforce the long-term benefits of tenofovir-based therapy. A recent study published in 2024, using data from over 3,000 patients, demonstrated that in individuals co-infected with HIV and HBV, initiating a tenofovir-based ART regimen (either TDF or TAF) was associated with a significantly reduced risk of developing advanced liver disease events, including cirrhosis and hepatocellular carcinoma, compared to non-tenofovir-based regimens.[69] This finding underscores the critical role of tenofovir in improving long-term outcomes in this high-risk population.

The future competitive landscape for tenofovir is dynamic. While it is currently an essential backbone of therapy, the success of potent, LA agents from novel classes (e.g., capsid inhibitors) could eventually lead to the development of NRTI-sparing long-acting regimens.[64] This potential paradigm shift positions the ongoing research into LA tenofovir as both an offensive strategy to improve current therapy and a defensive one to ensure the relevance of the NRTI class in the future of HIV treatment and prevention.

Conclusion

Tenofovir is a landmark achievement in antiviral drug development. Its journey from a potent but poorly absorbed molecule to a globally accessible, life-saving medicine, delivered through two generations of innovative prodrugs, has fundamentally altered the prognosis for millions of people living with or at risk for HIV and chronic hepatitis B. The evolution from TDF to TAF exemplifies a targeted approach to drug design, successfully engineering a molecule with an improved therapeutic index by optimizing its pharmacokinetic profile to enhance intracellular delivery while minimizing systemic toxicity.

Today, tenofovir stands as a cornerstone of international treatment and prevention guidelines. The choice between the low-cost, generic TDF and the branded, metabolically complex but renally and skeletally safer TAF presents a nuanced clinical decision that embodies the principles of personalized medicine and highlights the global challenges of health equity and access.

The future of tenofovir lies in overcoming the final barrier to ideal chronic disease management: adherence. The active pursuit of long-acting injectable and implantable formulations promises to usher in a new era of convenience and durability, potentially transforming HIV prevention and further solidifying tenofovir's legacy as one of the most impactful antiviral agents of its time. Its story is not merely one of a successful drug, but a reflection of the progress and future direction of modern pharmacology and global public health.

Works cited

1. Tenofovir | C9H14N5O4P | CID 464205 - PubChem, accessed July 17, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Tenofovir
2. Tenofovir: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 17, 2025, https://go.drugbank.com/drugs/DB14126
3. CAS Common Chemistry, accessed July 17, 2025, https://commonchemistry.cas.org/detail?cas_rn=147127-20-6
4. Tenofovir 147127-20-6 | Tokyo Chemical Industry (India) Pvt. Ltd., accessed July 17, 2025, https://www.tcichemicals.com/IN/en/p/T3006
5. Tenofovir Disoproxil Fumarate | C23H34N5O14P | CID 6398764 - PubChem, accessed July 17, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Tenofovir_Disoproxil_Fumarate
6. Generic Vemlidy Availability - Drugs.com, accessed July 17, 2025, https://www.drugs.com/availability/generic-vemlidy.html
7. Tenofovir Alafenamide PK Fact Sheet, accessed July 17, 2025, https://liverpool-hiv-hep.s3.amazonaws.com/prescribing_resources/pdfs/000/000/092/original/TAF_Fact_Sheet_%282022%29.pdf?1658330457
8. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults - Oxford Academic, accessed July 17, 2025, https://academic.oup.com/jac/article/69/5/1362/683435
9. Tenofovir Disoproxil | C19H30N5O10P | CID 5481350 - PubChem, accessed July 17, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Tenofovir-Disoproxil
10. Tenofovir Disoproxil | C19H30N5O10P | CID 5481350 - PubChem, accessed July 17, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/VIREAD
11. Tenofovir alafenamide - Wikipedia, accessed July 17, 2025, https://en.wikipedia.org/wiki/Tenofovir_alafenamide
12. Tenofovir-DF PK Fact Sheet, accessed July 17, 2025, https://liverpool-hiv-hep.s3.amazonaws.com/fact_sheets/pdfs/000/000/101/original/HIV_FactSheet_TDF_2016_Mar.pdf
13. What is the mechanism of Tenofovir? - Patsnap Synapse, accessed July 17, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-tenofovir
14. go.drugbank.com, accessed July 17, 2025, https://go.drugbank.com/drugs/DB00300#:~:text=Tenofovir%20diphosphate%20inhibits%20HIV%2D1,DNA%20chain%20termination%2024%2C%20Label.
15. Tenofovir disoproxil: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 17, 2025, https://go.drugbank.com/drugs/DB00300
16. Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed July 17, 2025, https://journals.asm.org/doi/10.1128/aac.48.1.124-129.2004
17. Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed July 17, 2025, https://journals.asm.org/doi/10.1128/aac.00005-16
18. Tenofovir (oral route) - Side effects & dosage - Mayo Clinic, accessed July 17, 2025, https://www.mayoclinic.org/drugs-supplements/tenofovir-oral-route/description/drg-20066221
19. Tenofovir (Viread), First Novel Antiviral Agent in Six Years, Approved by FDA, accessed July 17, 2025, https://www.treatmentactiongroup.org/resources/tagline/tagline-2001/tenofovir-viread-first-novel-antiviral-agent-in-six-years-approved-by-fda/
20. A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide - PMC, accessed July 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7163232/
21. Viread (tenofovir DF) dosing, indications, interactions, adverse effects, and more, accessed July 17, 2025, https://reference.medscape.com/drug/viread-tenofovir-df-342633
22. U.S. Food and Drug Administration Approves New Formulations of ..., accessed July 17, 2025, https://www.gilead.com/news/news-details/2012/us-food-and-drug-administration-approves-new-formulations-of-viread-for-use-by-children-living-with-hiv
23. Chronic Hepatitis B Unknown Status Phase Trials for Tenofovir (DB14126) - DrugBank, accessed July 17, 2025, https://go.drugbank.com/indications/DBCOND0028308/clinical_trials/DB14126?phase=&status=unknown_status
24. Tenofovir (Viread): Uses & Side Effects - Cleveland Clinic, accessed July 17, 2025, https://my.clevelandclinic.org/health/drugs/18926-tenofovir-disoproxil-fumarate-oral-powder
25. Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B - PMC, accessed July 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3002569/
26. Tenofovir disoproxil fumarate/Tenofovir alafenamide: MedlinePlus Drug Information, accessed July 17, 2025, https://medlineplus.gov/druginfo/meds/a602018.html
27. VEMLIDY® (tenofovir alafenamide) tablets, for oral use - accessdata.fda.gov, accessed July 17, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208464s008lbl.pdf
28. HIV Prevention Completed Phase 1 Trials for Tenofovir (DB14126) | DrugBank Online, accessed July 17, 2025, https://go.drugbank.com/indications/DBCOND0031674/clinical_trials/DB14126?phase=1&status=completed
29. Truvada (emtricitabine and tenofovir) FDA Approval History - Drugs.com, accessed July 17, 2025, https://www.drugs.com/history/truvada.html
30. HIV PrEP Medications and Dosing Options - Core Concepts, accessed July 17, 2025, https://www.hivprep.uw.edu/pdf/hiv-prep-fundamentals/hiv-prep-medication-options/core-concept/all
31. Truvada (emtricitabine tenofovir disoproxil fumarate) tablets label - accessdata.fda.gov, accessed July 17, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021752s035lbl.pdf
32. tenofovir disoproxil fumarate tablets - accessdata.fda.gov, accessed July 17, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/079071PI.pdf
33. Tenofovir Disoproxil Fumarate | Drug Lookup | Pediatric Care Online - AAP Publications, accessed July 17, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5569
34. Comparing initial antiretroviral regimens tenofovir or zidovudine as ..., accessed July 17, 2025, https://www.cochrane.org/evidence/CD008740_comparing-initial-antiretroviral-regimens-tenofovir-or-zidovudine-part-three-drug-combinations
35. Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate – is there a true difference in efficacy and safety? - Hivandmore.de, accessed July 17, 2025, https://www.hivandmore.de/kongresse/eacs2019/Pepperrell-BPD-1-1-Tenofovir-Alafenamide-versus-Tenofovir-Disoproxil-Fumarate.pdf
36. What Is the Difference Between TDF and TAF HIV Drugs? | Chalik ..., accessed July 17, 2025, https://www.chaliklaw.com/defective-drugs-lawyer/truvada/what-is-the-difference-between-tdf-and-taf-hiv-drugs/
37. What Are the Differences Between TDF and TAF? | The Dunken Law Firm, accessed July 17, 2025, https://www.thedunkenlawfirm.com/what-are-the-differences-between-tdf-and-taf/
38. When does the patent for Tenofovir Disoproxil expire? - Patsnap Synapse, accessed July 17, 2025, https://synapse.patsnap.com/article/when-does-the-patent-for-tenofovir-disoproxil-expire
39. Tenofovir Disoproxil Fumarate: Package Insert / Prescribing Info, accessed July 17, 2025, https://www.drugs.com/pro/tenofovir-disoproxil-fumarate.html
40. Tenofovir alafenamide (oral route) - Side effects & dosage - Mayo ..., accessed July 17, 2025, https://www.mayoclinic.org/drugs-supplements/tenofovir-alafenamide-oral-route/description/drg-20313020
41. Tenofovir alafenamide Advanced Patient Information - Drugs.com, accessed July 17, 2025, https://www.drugs.com/cons/tenofovir-alafenamide.html
42. Four-year analysis of tenofovir finds “favourable safety profile” - Aidsmap, accessed July 17, 2025, https://www.aidsmap.com/news/jun-2007/four-year-analysis-tenofovir-finds-favourable-safety-profile
43. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years | Request PDF - ResearchGate, accessed July 17, 2025, https://www.researchgate.net/publication/6290275_The_safety_of_tenofovir_disoproxil_fumarate_for_the_treatment_of_HIV_infection_in_adults_The_first_4_years
44. HIV/AIDS Treatment Guidelines | Clinicalinfo.HIV.gov, accessed July 17, 2025, https://clinicalinfo.hiv.gov/en/guidelines
45. Truvada dosage guidelines: Form, strengths, how to use, and more - Medical News Today, accessed July 17, 2025, https://www.medicalnewstoday.com/articles/drugs-truvada-dosage
46. Tenofovir alafenamide - TAF - Make Medicines Affordable, accessed July 17, 2025, https://makemedicinesaffordable.org/drug/tenofovir-alafenamide-taf/
47. Tenofovir Alafenamide Tablets - accessdata.fda.gov, accessed July 17, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/213845Orig1s000TAltr.pdf
48. Generic TENOFOVIR DISOPROXIL FUMARATE INN equivalents, pharmaceutical patent and freedom to operate - DrugPatentWatch, accessed July 17, 2025, https://www.drugpatentwatch.com/p/generic-api/TENOFOVIR+DISOPROXIL+FUMARATE
49. Generic Viread Availability - Drugs.com, accessed July 17, 2025, https://www.drugs.com/availability/generic-viread.html
50. Tenofovir DF Tablets – Manufacturer - AdvaCare Pharma, accessed July 17, 2025, https://www.advacarepharma.com/en/pharmaceuticals/tenofovir-disoproxil-fumarate-tablets
51. TLD or LTD (tenofovir disoproxil, lamivudine, dolutegravir) | Guides - HIV i-Base, accessed July 17, 2025, https://i-base.info/guides/14970
52. Generic Truvada Availability - Drugs.com, accessed July 17, 2025, https://www.drugs.com/availability/generic-truvada.html
53. Therapeutic Equivalence – Teva's Generic Version of ATRIPLA®, accessed July 17, 2025, https://www.tevahivgenerics.com/atripla-generic/therapeutic-equivalence
54. Antiretroviral Therapy (ART): Understanding HIV and AIDS Medications - WebMD, accessed July 17, 2025, https://www.webmd.com/hiv-aids/aids-hiv-medication
55. Guidelines and Recommendations | HIV Nexus - CDC, accessed July 17, 2025, https://www.cdc.gov/hivnexus/hcp/guidelines/index.html
56. Hepatitis B - Diagnosis and treatment - Mayo Clinic, accessed July 17, 2025, https://www.mayoclinic.org/diseases-conditions/hepatitis-b/diagnosis-treatment/drc-20366821
57. Chronic Hepatitis B | AASLD, accessed July 17, 2025, https://www.aasld.org/practice-guidelines/chronic-hepatitis-b
58. Guidelines and Recommendations | HIV Partners - CDC, accessed July 17, 2025, https://www.cdc.gov/hivpartners/php/guidelines/index.html
59. HIV and AIDS - World Health Organization (WHO), accessed July 17, 2025, https://www.who.int/news-room/fact-sheets/detail/hiv-aids
60. Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis - PMC - PubMed Central, accessed July 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12224115/
61. P-3 Effectiveness and safety of tenofovir alafenamide/emtricitabine/bictegravir as first line regimen in people with HIV: a retrospective observational study | Sexually Transmitted Infections, accessed July 17, 2025, https://sti.bmj.com/content/100/Suppl_1/A151
62. Fundamental aspects of long-acting tenofovir alafenamide delivery ..., accessed July 17, 2025, https://pure.johnshopkins.edu/en/publications/fundamental-aspects-of-long-acting-tenofovir-alafenamide-delivery
63. The Promise of Long Acting Antiretroviral Therapies: From Need to Manufacture - PMC, accessed July 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6571075/
64. Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV Prevention Option Offering 6 Months of Protection - Gilead Sciences, accessed July 17, 2025, https://www.gilead.com/news/news-details/2025/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection
65. Prodrug approaches for the development of a long-acting drug delivery systems - PMC, accessed July 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10498988/
66. Prodrug Approaches for Long-Acting Antiretroviral Drugs - University of Nebraska Medical Center, accessed July 17, 2025, https://www.unmc.edu/pharmacology/_documents/prodrugs_approaches.pdf
67. DEVELOPMENT OF PRODRUG APPROACHES FOR LONG-ACTING NANOFORMULATIONS OF EMTRICITABINE-BASED REGIMENS - LEAP, accessed July 17, 2025, https://longactinghiv.org/content/development-prodrug-approaches-long-acting-nanoformulations-emtricitabine-based-regimens
68. Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation, accessed July 17, 2025, https://www.dovepress.com/synthesis-and-characterization-of-a-long-acting-emtricitabine-prodrug--peer-reviewed-fulltext-article-IJN
69. Tenofovir | Advanced Liver Disease Events in People with HIV and ..., accessed July 17, 2025, https://www.springermedicine.com/tenofovir/hepatitis-b/advanced-liver-disease-events-in-people-with-hiv-and-hepatitis-b/51224716